In this Issue:
PegIFN-β-1a for relapsing remitting MS
A CGRP monoclonal antibody for migraine prevention?
Tozadenant reduces ‘off-time’ in PD
Mental incapacity in brain tumour patients
Fulranumab in diabetic peripheral neuropathic pain
Natalizumab: clinical efficacy issues in relapsing-remitting MS
ICD prevalence with different dopamine agonists
New FTD clinical diagnostic criteria
Brain tumour location and mentalisation processes
Critical illness myopathy and polyneuropathy
Please login below to download this issue (PDF)